Previous 10 | Next 10 |
2023-03-08 12:54:43 ET Gainers: Kimball International ( KBAL ) +83% . Arlo Technologies ( ARLO ) +45% . Diversey ( DSEY ) +37% . Maxeon ( MAXN ) +32% . LifeStance ( LFST ) +26% . Mesoblast ( MESO ) +26% . Vertex (...
2023-03-08 10:06:57 ET Gainers: Fresh Tracks Therapeutics ( FRTX ) +42% . LifeStance Health Group ( LFST ) +24% . Assure Holdings ( IONM ) +19% . Mesoblast ( MESO ) +19% . Treace Medical Concepts ( TMCI ) +17% . Losers: ...
2023-03-08 08:36:27 ET Fresh Tracks Therapeutics ( FRTX ) +83% on announcing positive topline results from single and multiple ascending dose parts of phase 1 study of Oral DYRK1A Inhibitor FRTX-02. Kimball International ( KBAL ) +75% HNI to acquire Kimball i...
2023-03-08 05:34:38 ET The U.S. Food and Drug Administration (FDA) accepted to review Mesoblast's ( NASDAQ: MESO ) resubmitted application seeking approval of remestemcel-L to treat children with steroid-refractory acute graft versus host disease (SR-aGVHD), more than ...
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Therapeutic Products (OTP) has accepted the...
Mesoblast Limited. (MESO) Q2 2023 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Silviu Itescu – Chief Executive Officer Andrew Chaponnel – Chief Financial Officer Conference Call Participants Edward Tenthoff – P...
The following slide deck was published by Mesoblast Limited in conjunction with their 2023 Q2 earnings call. For further details see: Mesoblast Limited 2023 Q2 - Results - Earnings Call Presentation
NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended December 31, 2022. Dr. Silviu Itescu, Chief Execut...
NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed journal for cardiovascular medicine, the ...
NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that two studies on the remestemcel-L development program for the treatment of children with steroid-refractory acute gra...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...